In the case of vaginal treatment, levels of aromatase (the enzyme that converts androgen to estrogen) expressed in the endometrium appear to be minimal, indicating a low risk of endometrial hyperplasia or cancer. This evidence concerns the gene CYP19A1 and cancer.